Cost-effectiveness analysis of influenza A (H1N1) chemoprophylaxis in unified health system in Brazil
PDF (Inglês)

Palavras-chave

Cost-effectiveness
Influenza
Brazil.

Como Citar

VECOSO, Luisa Von Zuben; GALVAO, Tais Freire; SILVA, Marcus; SILVA, Everton; RESENDE, Mariangela. Cost-effectiveness analysis of influenza A (H1N1) chemoprophylaxis in unified health system in Brazil. Revista dos Trabalhos de Iniciação Científica da UNICAMP, Campinas, SP, n. 26, 2019. DOI: 10.20396/revpibic262018926. Disponível em: https://econtents.sbu.unicamp.br/eventos/index.php/pibic/article/view/926. Acesso em: 18 mar. 2026.

Resumo

BACKGROUND: Oseltamivir and zanamivir have indication for treating symptomatic flu and in prophylaxis in epidemics for groups with high risk of complications. METHODS: Effectiveness data was identified in literature review, and costs were obtained from official systems and micro-costing. RESULTS: We adopted a decision-tree model to assess the effectiveness of chemoprophylaxis in Brazilian Unified Health System (SUS) perspective with willingness to pay BRL 30,000.00/QALY. The incremental cost-effectiveness ratio for chemoprophylaxis compared to no prophylaxis was - 2,921.14/QALY. CONCLUSION: Chemoprophylaxis is cost-effective in Brazilian scenario.

PDF (Inglês)
Creative Commons License
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.

Copyright (c) 2019 Luisa Von Zuben Vecoso, Tais Freire Galvao